Somatomedin A levels in patients with Cushing's disease

Acta Endocrinol (Copenh). 1981 May;97(1):12-7. doi: 10.1530/acta.0.0970012.

Abstract

The serum levels of immunoreactive somatomedin A (SMA) in 23 patients with Cushing's disease, aged 6-61 years, were within the range of healthy subjects for their ages. No correlation was found between SMA and the excretion of cortisol. After im administration of hGH (8 IU = 4 mg) daily for 3 days there was a significant rise in SMA, both determined by radioimmunoassay and radioreceptor assay. Thus no impairment was found in the GH-dependent SMA levels or the ability of hGH to generate somatomedin, which indicates that the growth retarding effect of cortisol is most likely due to a direct effect on the tissue. After treatment with stereotactic radiation to the hypophysis there was a significant decrease in cortisol excretion without any change in SMA levels, indicating the possibility to achieve a selective impairment of the ACTH-cortisol axis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenocorticotropic Hormone / metabolism
  • Adult
  • Age Factors
  • Child
  • Cushing Syndrome / blood*
  • Cushing Syndrome / radiotherapy
  • Female
  • Growth Hormone / pharmacology
  • Humans
  • Hydrocortisone / urine
  • Male
  • Middle Aged
  • Somatomedins / blood*

Substances

  • Somatomedins
  • Adrenocorticotropic Hormone
  • Growth Hormone
  • Hydrocortisone